PCSK9 and familial hypercholesterolemia: For primary prevention in very high-risk patients (e.g., familial hypercholesterolemia), targets < 55 mg/dL are justified PCSK9 inhibitors and should be considered earlier in the treatment algorithm for high-risk patients, not just as a last-line therapy.